X4 Pharmaceuticals (NASDAQ:XFOR) Trading Up 0.7% - Time to Buy?

Key Points

• X4 Pharmaceuticals shares rose 0.7% to $4.13 on Monday with light volume (~229k shares, down 47% vs. average); the company has a market cap of ~$375.5M and 50/200-day moving averages near $3.78/$3.71.
• Analyst views are mixed—three Buys, one Hold, one Sell—with a consensus price target of $8.50 and Guggenheim initiating coverage with a $12 target.
• The clinical-stage biopharma is advancing mavorixafor and topped quarterly estimates (EPS -$0.22 vs. -$0.36; revenue $2.57M vs. $1.68M) but remains unprofitable with negative margins and ROE.

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Get Free Report)'s share price was up 0.7% during trading on Monday . The stock traded as high as $4.23 and last traded at $4.13. Approximately 228,932 shares changed hands during mid-day trading, a decline of 47% from the average daily volume of 431,254 shares. The stock had previously closed at $4.10.

Analyst Ratings Changes

Several equities analysts have commented on XFOR shares. Wall Street Zen raised X4 Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday, March 21st. Weiss Ratings reissued a "sell (d-)" rating on shares of X4 Pharmaceuticals in a research report on Friday, March 27th. Finally, Guggenheim started coverage on X4 Pharmaceuticals in a research report on Monday, March 9th. They set a "buy" rating and a $12.00 price target on the stock. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $8.50.

X4 Pharmaceuticals Stock Up 0.7%

The company has a current ratio of 10.16, a quick ratio of 9.98 and a debt-to-equity ratio of 0.41. The business has a 50-day moving average price of $3.78 and a 200-day moving average price of $3.71. The firm has a market cap of $375.50 million, a P/E ratio of -0.95 and a beta of 0.32.

X4 Pharmaceuticals (NASDAQ:XFOR - Get Free Report) last posted its quarterly earnings results on Tuesday, March 17th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.36) by $0.14. X4 Pharmaceuticals had a negative return on equity of 115.27% and a negative net margin of 225.55%.The business had revenue of $2.57 million for the quarter, compared to the consensus estimate of $1.68 million. On average, equities analysts forecast that X4 Pharmaceuticals, Inc. will post -0.68 EPS for the current fiscal year.

Institutional Investors Weigh In On X4 Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the stock. Rhumbline Advisers boosted its position in X4 Pharmaceuticals by 5.4% during the first quarter. Rhumbline Advisers now owns 188,415 shares of the company's stock valued at $44,000 after purchasing an additional 9,690 shares in the last quarter. Indivisible Partners bought a new position in shares of X4 Pharmaceuticals during the 4th quarter worth approximately $40,000. Squarepoint Ops LLC bought a new position in shares of X4 Pharmaceuticals during the 4th quarter worth approximately $50,000. Two Sigma Investments LP bought a new position in shares of X4 Pharmaceuticals during the 3rd quarter worth approximately $47,000. Finally, Palumbo Wealth Management LLC raised its stake in shares of X4 Pharmaceuticals by 18.9% during the 4th quarter. Palumbo Wealth Management LLC now owns 113,357 shares of the company's stock worth $453,000 after acquiring an additional 18,030 shares in the last quarter. Institutional investors own 72.03% of the company's stock.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company's lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström's macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.